Chaquera Leshay Kent

Chaquera Kent practices at Tampa General Hospital in Tampa, Florida, part of Tampa General Hospital.

Chaquera Kent's NPI, 1780328351, was assigned on April 20, 2022. Chaquera Kent holds Florida license APRN11010258.

Chaquera Kent's primary practice is Tampa General Hospital, at 1 Tampa General Cir, Tampa, FL 33606 in Hillsborough County. The practice phone is (813) 844-7000.

Chaquera Kent's primary practice is Tampa General Hospital in Tampa, Florida, part of Tampa General Hospital. The medical group on file is Tampa General Medical Group (TGMG). Dmand AI also links Chaquera Kent to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Chaquera Kent practices, 2 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Chaquera Kent's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Chaquera Kent is licensed in Florida.

CMS data shows 80 Medicare services from Chaquera Kent across 2 procedure codes in 2024, all of them office visits, for 44 Medicare patients. Medicare paid $4,381 for them. Every service was in an office.

CMS counts 44 Medicare patients who saw Chaquera Kent in 2024. The largest group is under 65, with 27 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Chaquera Kent's median patient age at 49, with 81% women.

In 2024, Chaquera Kent wrote 218 Medicare Part D claims for 67 patients. 65% of them were for generic drugs. CMS names the drug for 137 of them, across 4 drugs with 11 or more claims each, at $58,345 in total drug cost.

Chaquera Kent accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Chaquera Kent as offering telehealth.

CMS Open Payments shows 4 general payments to Chaquera Kent from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Eli Lilly and Company paid the most, $247.